It’s a new $DAWN for Day One as startup pivots to an IPO for more funding to back its work in pediatric cancer

Pediatric cancer biotech Day One Pharmaceuticals is headed for Nasdaq, in a move that comes less than three months after their work on a brain …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

It’s a new $DAWN for Day One as start­up piv­ots to an IPO for more fund­ing to back its work in pe­di­atric can­cer